GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kabra Drugs Ltd (BOM:524322) » Definitions » ROA %

Kabra Drugs (BOM:524322) ROA % : -62.07% (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Kabra Drugs ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Kabra Drugs's annualized Net Income for the quarter that ended in Dec. 2023 was ₹-4.36 Mil. Kabra Drugs's average Total Assets over the quarter that ended in Dec. 2023 was ₹7.03 Mil. Therefore, Kabra Drugs's annualized ROA % for the quarter that ended in Dec. 2023 was -62.07%.

The historical rank and industry rank for Kabra Drugs's ROA % or its related term are showing as below:

BOM:524322' s ROA % Range Over the Past 10 Years
Min: -71.9   Med: -7.24   Max: 1.7
Current: -71.9

During the past 13 years, Kabra Drugs's highest ROA % was 1.70%. The lowest was -71.90%. And the median was -7.24%.

BOM:524322's ROA % is ranked worse than
90.1% of 1081 companies
in the Drug Manufacturers industry
Industry Median: 1.7 vs BOM:524322: -71.90

Kabra Drugs ROA % Historical Data

The historical data trend for Kabra Drugs's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kabra Drugs ROA % Chart

Kabra Drugs Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.36 -4.11 -12.78 -17.39 -47.15

Kabra Drugs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.12 -80.90 -69.41 -76.35 -62.07

Competitive Comparison of Kabra Drugs's ROA %

For the Drug Manufacturers - Specialty & Generic subindustry, Kabra Drugs's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kabra Drugs's ROA % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kabra Drugs's ROA % distribution charts can be found below:

* The bar in red indicates where Kabra Drugs's ROA % falls into.



Kabra Drugs ROA % Calculation

Kabra Drugs's annualized ROA % for the fiscal year that ended in Mar. 2023 is calculated as:

ROA %=Net Income (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=-3.379/( (7.297+7.036)/ 2 )
=-3.379/7.1665
=-47.15 %

Kabra Drugs's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-4.364/( (7.031+0)/ 1 )
=-4.364/7.031
=-62.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Kabra Drugs  (BOM:524322) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-4.364/7.031
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-4.364 / 0)*(0 / 7.031)
=Net Margin %*Asset Turnover
=N/A %*0
=-62.07 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Kabra Drugs ROA % Related Terms

Thank you for viewing the detailed overview of Kabra Drugs's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kabra Drugs (BOM:524322) Business Description

Traded in Other Exchanges
N/A
Address
Swaminathan Street, No:3, 2nd Floor, West Mambalam, Chennai, TN, IND, 600033
Kabra Drugs Ltd is an India-based drug manufacturing company. It is engaged in the business of Permaculture manufacturing and trading in pharma related products. Geographically, all the company operations are carried out in India. It generates revenue from the sale of materials principally in India. The company plant for manufacturing the drugs is located in the Indian state of Madhya Pradesh. Its products include Cardiovascular Drugs, Anti-Infective Drugs, Oncology Drugs, Gastroenterologic Drugs, Hormonal Drugs, etc.

Kabra Drugs (BOM:524322) Headlines

No Headlines